Brief: Pliant Therapeutics Announces Positive Dsmb Safety Review And Initiation Of Enrollment Of Phase 2A Trial Of Bexotegrast (PLN-74809) At 320 Mg Dose In Primary Sclerosing Cholangitis

Pliant Therapeutics

13/03/2023 12:14

March 13 (Reuters) - Pliant Therapeutics Inc  PLRX.O :
    * PLIANT THERAPEUTICS ANNOUNCES POSITIVE DSMB SAFETY REVIEW
AND
INITIATION OF ENROLLMENT OF PHASE 2A TRIAL OF BEXOTEGRAST
(PLN-74809) AT 320 MG DOSE IN PRIMARY SCLEROSING CHOLANGITIS

Source text for Eikon:  ID:nGNX3cgypr 
Further company coverage:  PLRX.O 

 ((Reuters.Briefs@thomsonreuters.com;;))